medigraphic.com

2011, Número 1

<< Anterior Siguiente >>

Rev Med MD 2011; 2.3 (1)


Ácidos grasos: ¿amigos o enemigos del cáncer?

Meza-Guillen D, Martínez-García EA, Juárez-Rojas JG

Idioma: Español
Referencias bibliográficas: 36
Paginas: 10-15
Archivo PDF: 548.27 Kb.


RESUMEN

El cáncer es el crecimiento celular descontrolado originado por diversos factores etiológicos. Algunos estudios han mostrado que los componentes nutritivos y no nutritivos de la dieta pueden promover o retrasar el desarrollo del cáncer en personas con predisposición genética. Las grasas se han contraindicado durante la terapia farmacológica contra el cáncer, incluso englobando a algunos ácidos grasos que han mostrado resultados benéficos en investigaciones de intervención para el tratamiento del cáncer. Estos son los ácidos grasos poliinsaturados, que se asocian con la reducción en la incidencia de proliferación de melanomas malignos de manera significativa, a través de la supresión de la expresión de cicloxigenasa-2 en tumores, la disminución de la expresión de AP-1 y RAS, la promoción de la diferenciación de células cancerosas, apoptosis de células malignas y disminución de la caquexia. En nuestra población existe ingesta deficiente de estos nutrientes incluso en sujetos sanos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.Williams MT, Hord NG. The role of dietary factors in cancer prevention: beyond fruits and vegetables. Nutr Clin Pract. 2005;20:451-459.

  2. 2.Instituto Nacional de Estadística y Geografía, Instituto Nacional de las Mujeres. Mujeres y hombres en México 2010. Informe del INEGI. México 2010:15.

  3. 3.Riezzo G, Chiloiro M, Russo F. Functional foods: salient features and clinical applications. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5:331-337.

  4. 4.Parodi PW. Cows' milk fat components as potential anticarcinogenic agents. J Nutr. 1997;127:1055-1060.

  5. 5.Ip C, Singh M, Thompson HJ, Scimeca JA. Conjugated linoleic acid suppresses mammary carcinogenesis and proliferative activity of the mammary gland in the rat. Cancer Res. 1994;54:1212-1215

  6. 6.Hardman WE. Omega-3 fatty acids to augment cancer therapy. J Nutr. 2002;132:3508S-3512S.

  7. 7.Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet. 2001;357:539-545.

  8. 8.Blobe GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev. 1994;13:411-431.

  9. 9.Hoon DS, Ferris R, Tanaka R, Chong KK, Alix-Panabières C, Pantel K. Molecular mechanisms of metástasis. J Surg Oncol. 2011;103:508-517.

  10. 10.Inagaki Y, Xu H, Nakata M, Seyama Y, Hasegawa K, Sugawara Y, Tang W, Kokudo N. Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers. Biosci Trends. 2009;3:220-232.

  11. 11.Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study Group. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006;83:1345–1350.

  12. 12.von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1:159–167.

  13. 13.Santarpia L, Contaldo F, Pasanisi F. Nutritional screening and early treatment of malnutrition in cancer patients. J Cachexia Sarcopenia Muscle. 2011; 2:27–35.

  14. 14.Bougnoux P, Chajès V, Germain E, Hubert B, Lhuillery C, Le Floch O, et al. Cytotoxic drug efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma. Lipids. 1999;34 Suppl:S109.

  15. 15.Skipworth RJE, Stewart GD, Dejong CHC, Preston T, Fearon KC. Pathophysiology of cancer cachexia: much more than host-tumor interaction?. Clin Nutr. 2007;26:667–676.

  16. 16.Marín-Caro MM, Laviano A, Pichard C. Nutritional intervention and quality of life in adult oncology patients. Clin Nutr. 2007;26:289–301.

  17. 17.Santarpia L, Alfonsi L, et al. Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition. Nutrition. 2006;22:355–360.

  18. 18.Gaidos JK, Gaidos JK, Draganov PV. Treatment of malignant gastric outlet obstruction with endoscopically placed self-expandable metal stents. World J Gastroenterol 2009;15:4365–4371.

  19. 19.Tvrzicka E, Kremmyda LS, Stankova B, Zak A. Fatty acids as biocompounds: their role in human metabolism, health and disease - a review. Part 1: classification, dietary sources and biological functions. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155:117-130.

  20. 20.Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr. 2004;79:935-945.

  21. 21.Rose DP, Connolly JM. Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in cultura. Cancer Res. 1990;50:7139-7144.

  22. 22.Pauwels EK, Kairemo K. Fatty acid facts, part II: role in the prevention of carcinogenesis, or, more fish on the dish?. Drug News Perspect. 2008;21:504-510.

  23. 23.Nishino H, Murakoshi M, Mou XY, Wada S, Masuda M, Ohsaka Y, et al. Cancer prevention by phytochemicals. Oncology. 2005;69 Suppl 1:38-40.

  24. 24.Chen ZY, Istfan NW. Docosahexaenoic acid is a potent inducer of apoptosis in HT-29 colon cancer cells. Prostaglandins Leukot Essent Fatty Acids. 2000;63:301-318.

  25. 25.Sauer LA, Dauchy RT, Blask DE. Mechanism for the antitumor and anticachectic effects of n-3 fatty acids. Cancer Res. 2000;60:5289-5295.

  26. 26.Wirfält E, Mattisson I, et al. Postmenopausal breast cancer is associated with high intakes of omega6 fatty acids (Sweden). Cancer Causes Control. 2002;13:883-893.

  27. 27.Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest. 2007;117:1866-1875.

  28. 28.Hague A, Paraskeva C. The short-chain fatty acid butyrate induces apoptosis in colorectal tumour cell lines. Eur J Cancer Prev. 1995;4:359-364.

  29. 29.Smith TJ, Yang GY, Seril DN, Liao J, Kim S. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis by dietary olive oil and squalene. Carcinogenesis. 1998;19:703-706.

  30. 30.Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908-7916.

  31. 31.Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition. 1996;12(1 Suppl):S27-30.

  32. 32.Collett ED, Davidson LA, Fan YY, Lupton JR, Chapkin RS. n-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am J Physiol Cell Physiol. 2001;280:C1066-C1075.

  33. 33.Dimri M, Bommi PV, Sahasrabuddhe AA, Khandekar JD, Dimri GP. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Carcinogenesis. 2010;31:489-495.

  34. 34.de Gŏmez Dumm IN, Brenner RR. Oxidative desaturation of alpha-linoleic, linoleic, and stearic acids by human liver microsomes. Lipids. 1975;10:315-317.

  35. 35.Calder PC, Davis J, et al. Dietary fish oil suppresses human colon tumour growth in athymic mice. Clin Sci (Lond). 1998;94:303-311.

  36. 36.Bagga D, Capone S, Wang HJ, Heber D, Lill M, Chap L, et al. Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer. J Natl Cancer Inst. 1997;89:1123-1131.




2020     |     www.medigraphic.com